TOFACITINIB CITRATE
| Brand name | XELJANZ |
|---|---|
| Active ingredient | TOFACITINIB CITRATE |
| Strength | EQ 10MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | May 2018 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| RE41783*PED | June 2026 | — |
| RE41783 | December 2025 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.